Literature DB >> 29133563

A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.

N C Ferreira1, L M Ascari1, A G Hughson2, G R Cavalheiro3, C F Góes1, P N Fernandes1, J R Hollister2, R A da Conceição1, D S Silva4, A M T Souza1, M L C Barbosa1, F A Lara4, R A P Martins3, B Caughey2, Y Cordeiro5.   

Abstract

The search for antiprion compounds has been encouraged by the fact that transmissible spongiform encephalopathies (TSEs) share molecular mechanisms with more prevalent neurodegenerative pathologies, such as Parkinson's and Alzheimer's diseases. Cellular prion protein (PrPC) conversion into protease-resistant forms (protease-resistant PrP [PrPRes] or the scrapie form of PrP [PrPSc]) is a critical step in the development of TSEs and is thus one of the main targets in the screening for antiprion compounds. In this work, three trimethoxychalcones (compounds J1, J8, and J20) and one oxadiazole (compound Y17), previously identified in vitro to be potential antiprion compounds, were evaluated through different approaches in order to gain inferences about their mechanisms of action. None of them changed PrPC mRNA levels in N2a cells, as shown by reverse transcription-quantitative real-time PCR. Among them, J8 and Y17 were effective in real-time quaking-induced conversion reactions using rodent recombinant PrP (rPrP) from residues 23 to 231 (rPrP23-231) as the substrate and PrPSc seeds from hamster and human brain. However, when rPrP from residues 90 to 231 (rPrP90-231), which lacks the N-terminal domain, was used as the substrate, only J8 remained effective, indicating that this region is important for Y17 activity, while J8 seems to interact with the PrPC globular domain. J8 also reduced the fibrillation of mouse rPrP23-231 seeded with in vitro-produced fibrils. Furthermore, most of the compounds decreased the amount of PrPC on the N2a cell surface by trapping this protein in the endoplasmic reticulum. On the basis of these results, we hypothesize that J8, a nontoxic compound previously shown to be a promising antiprion agent, may act by different mechanisms, since its efficacy is attributable not only to PrP conversion inhibition but also to a reduction of the PrPC content on the cell surface.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  PrP; RT-QuIC; antiprion; antiscrapie; antiscrapie compounds; prion protein; prion strains; prions; therapy

Mesh:

Substances:

Year:  2018        PMID: 29133563      PMCID: PMC5786768          DOI: 10.1128/AAC.01441-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  75 in total

1.  Scrapie strains maintain biological phenotypes on propagation in a cell line in culture.

Authors:  C R Birkett; R M Hennion; D A Bembridge; M C Clarke; A Chree; M E Bruce; C J Bostock
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

2.  Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner.

Authors:  Yuri Kawasaki; Keiichi Kawagoe; Chun-jen Chen; Kenta Teruya; Yuji Sakasegawa; Katsumi Doh-ura
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

3.  The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc).

Authors:  Jessie A Turnbaugh; Ursula Unterberger; Paula Saá; Tania Massignan; Brian R Fluharty; Frederick P Bowman; Michael B Miller; Surachai Supattapone; Emiliano Biasini; David A Harris
Journal:  J Neurosci       Date:  2012-06-27       Impact factor: 6.167

Review 4.  Developing Therapeutics for PrP Prion Diseases.

Authors:  Kurt Giles; Steven H Olson; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 5.  Strain specificity and drug resistance in anti-prion therapy.

Authors:  Lakshmi Miller-Vedam; Sina Ghaemmaghami
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

6.  Influence of surface functionality of poly(propylene imine) dendrimers on protease resistance and propagation of the scrapie prion protein.

Authors:  Marlies Fischer; Dietmar Appelhans; Simona Schwarz; Barbara Klajnert; Maria Bryszewska; Brigitte Voit; Mark Rogers
Journal:  Biomacromolecules       Date:  2010-05-10       Impact factor: 6.988

Review 7.  Prion diseases--close to effective therapy?

Authors:  Neil R Cashman; Byron Caughey
Journal:  Nat Rev Drug Discov       Date:  2004-10       Impact factor: 84.694

8.  Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein.

Authors:  H Büeler; M Fischer; Y Lang; H Bluethmann; H P Lipp; S J DeArmond; S B Prusiner; M Aguet; C Weissmann
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

9.  c-Myc regulates cell proliferation during lens development.

Authors:  Gabriel R Cavalheiro; Gabriel E Matos-Rodrigues; Anielle L Gomes; Paulo M G Rodrigues; Rodrigo A P Martins
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

10.  Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches.

Authors:  Natalia C Ferreira; Icaro A Marques; Wesley A Conceição; Bruno Macedo; Clarice S Machado; Alessandra Mascarello; Louise Domeneghini Chiaradia-Delatorre; Rosendo Augusto Yunes; Ricardo José Nunes; Andrew G Hughson; Lynne D Raymond; Pedro G Pascutti; Byron Caughey; Yraima Cordeiro
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

View more
  6 in total

1.  Multimodal small-molecule screening for human prion protein binders.

Authors:  Andrew G Reidenbach; Michael F Mesleh; Dominick Casalena; Sonia M Vallabh; Jayme L Dahlin; Alison J Leed; Alix I Chan; Dmitry L Usanov; Jenna B Yehl; Christopher T Lemke; Arthur J Campbell; Rishi N Shah; Om K Shrestha; Joshua R Sacher; Victor L Rangel; Jamie A Moroco; Murugappan Sathappa; Maria Cristina Nonato; Kong T Nguyen; S Kirk Wright; David R Liu; Florence F Wagner; Virendar K Kaushik; Douglas S Auld; Stuart L Schreiber; Eric Vallabh Minikel
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

2.  Poly-L-histidine inhibits prion propagation in a prion-infected cell line.

Authors:  Ryo Honda; Kei-Ichi Yamaguchi; Abdelazim Elsayed Elhelaly; Mitsuhiko Fuji; Kazuo Kuwata
Journal:  Prion       Date:  2018-08-17       Impact factor: 3.931

3.  Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies.

Authors:  Luise Linsenmeier; Behnam Mohammadi; Mohsin Shafiq; Karl Frontzek; Julia Bär; Amulya N Shrivastava; Markus Damme; Feizhi Song; Alexander Schwarz; Stefano Da Vela; Tania Massignan; Sebastian Jung; Angela Correia; Matthias Schmitz; Berta Puig; Simone Hornemann; Inga Zerr; Jörg Tatzelt; Emiliano Biasini; Paul Saftig; Michaela Schweizer; Dmitri Svergun; Ladan Amin; Federica Mazzola; Luca Varani; Simrika Thapa; Sabine Gilch; Hermann Schätzl; David A Harris; Antoine Triller; Marina Mikhaylova; Adriano Aguzzi; Hermann C Altmeppen; Markus Glatzel
Journal:  Sci Adv       Date:  2021-11-24       Impact factor: 14.136

Review 4.  The role of prion strain diversity in the development of successful therapeutic treatments.

Authors:  Sara A M Holec; Alyssa J Block; Jason C Bartz
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-28       Impact factor: 3.622

5.  Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease.

Authors:  Bradley R Groveman; Natalia C Ferreira; Simote T Foliaki; Ryan O Walters; Clayton W Winkler; Brent Race; Andrew G Hughson; Gianluigi Zanusso; Cathryn L Haigh
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.996

Review 6.  Natural and Synthetic Derivatives of Hydroxycinnamic Acid Modulating the Pathological Transformation of Amyloidogenic Proteins.

Authors:  Vladimir I Muronetz; Kseniya Barinova; Sofia Kudryavtseva; Maria Medvedeva; Aleksandra Melnikova; Irina Sevostyanova; Pavel Semenyuk; Yulia Stroylova; Matej Sova
Journal:  Molecules       Date:  2020-10-12       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.